U.K. suspends Teva's hypothyroid generic; Lupin settles Glumetza patent fight;

@FiercePharma: Heinz might want pieces of the Pfizer nutrition business if they become available for antitrust reasons, FT reports. Story (reg. req.) | Follow @FiercePharma

> U.K. regulators suspended Teva Pharmaceutical Industries' ($TEVA) clearance for a version of the hypothyroidism drug levothyroxine on worries that the tablets might have dissolution problems affecting release of the active ingredient. News

> India's Lupin has won the right to launch its version of the diabetes drug Glumetza by 2016 in a patent settlement with Depomed and Santarus. Report

> Australian officials should revamp their pricing policies to take full advantage of low-cost generics, an economist advised. News

> A Washington state law requiring pharmacists to dispense emergency contraception despite their religious beliefs was struck down by a U.S. judge. Item

> Up to 60 R&D staff members will lose their jobs as Genzyme pulls out of Cambridge, England, and consolidates research into four global hubs. Story

> Questcor Pharmaceuticals reported a leap in quarterly profits on strong sales of its Acthar product, an injectable approved for multiple sclerosis exacerbations and nephrotic syndrome, among others. News

Biotech News

@FierceBiotech: Combined vaccine has low seizure risk in babies. News | Follow @FierceBiotech

@JohnCFierce: Simos Simeonidis at Cowen says he's surprised by the VVUS vote, but "we see FDA approval by April 17 as pretty much a done deal." | Follow @JohnCFierce

@RyanMFierce: $VVUS bulls being handsomely rewarded this morning. Stock up 110.5% at last glance in a.m. trading. Story | Follow @RyanMFierce

@FierceMedDev: Colonoscopy Can Lower Rate of Cancer Deaths by Half. Story via @BloombergNews (see Enzo story). News | Follow @FierceMedDev

> Satori snags $15M to fuel a trial on Alzheimer's drug. News

Vaccines News

> Vaccines mean that India celebrates its first year free of polio. Report

> World's first kala azar vaccine enters the clinic. Story

> Universal flu vaccine in first trial in the elderly, boosts responses. Item

> Nimenrix meningitis vaccine edges closer to the market for GSK. Article

> Prostate cancer vaccine teams up with antibody. Story

> Norovirus gets it in the nose. News

Manufacturing News

> Teva expected to pay big bucks for decision to use oversized vials. Report

> J&J Recall: Manufacturing issues believed behind CEO departure. Item

> Shire's $200 million Leed certified plant gets EMA nod. Story

> Pharmacists may seek arbitration to get recall costs from GSK. News

> Ranbaxy's manufacturing mess results in $606 million loss. Article

> FDA triples list of banned Chinese heparin ingredient makers. More

CRO News

> FDA cracks down on Chinese heparin material providers. News

> Ex-AstraZeneca researchers launch new CRO. Report

> ACRO blasts new rules that reveal docs' drug research payments. More

And Finally... Tuberculosis is staging a comeback in London, as some neighborhoods have infection rates similar to those in African countries in which the disease is endemic. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.